MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

MyoKardia Inc. (NASDAQ:MYOK) reported data from the 10 patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the second cohort of the open-label, U.S. Phase II PIONEER-HCM trial showing that lower doses of oral mavacamten met the primary and several secondary endpoints. The

Read the full 421 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE